Zydus Cadila entity to sell its India focused animal health business to a consortium
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The agreement will help ensure wider reach and access to patients in India
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated